Alan raises €480m at €5.5bn, Europe's largest healthtech round in 2026, pending regulatory sign-off

Summary

French healthtech platform Alan agreed a €480m Series G on 25 June 2026 at a €5.5bn post-money valuation, the highest valuation ever recorded for a European healthtech startup. Prosus, the Dutch consumer-internet holding company, led the round; Index Ventures, Teachers' Venture Growth and Dara Holdings co-invested. The round remains conditional on sign-off from French financial regulators because Alan offers insurance products governed under French financial regulation. Founded in 2016, Alan started as a digital health insurer in France and has since expanded to Spain, Belgium and Canada, covering 1.1 million users across a team of 850. Annual recurring revenue crossed €800m in Q1 2026, up 53% year-over-year, and the company is profitable in France. The round reflects a product evolution: Alan now combines health insurance with primary-care access, mental-health sessions and preventive-health coaching in a single app, a model closer to a US-style health maintenance organisation than a conventional European insurer. The Paris Tech ecosystem anchors the raise; Alan is among the highest-valued French startups alongside Mistral and Contentsquare.

The split

European tech press (Sifted, Tech.eu, TheNextWeb) treats the raise as a landmark for continental healthtech and a vindication of the regulated-insurance-as-technology model that Alan has championed since 2016. Sifted emphasises the French regulatory condition as a structural feature of the market, not a risk: the AMF process is routine. TheNextWeb's angle is the prevention pivot, arguing that the HMO-like product expansion is what separates Alan from simple insurtech. US coverage is thin, reflecting how few US investors have followed this market. The missing voice is from Germany or the UK, markets where Alan does not yet operate and where competitors like Ottonova and Bupa operate with different models.

By the numbers

• €480m, Series G round size.
• €5.5bn, post-money valuation.
• €800m+, ARR as of Q1 2026 (+53% YoY).
• 1.1m, users across France, Spain, Belgium and Canada.
• 850, employees.
• Profitable in France.
• 4, markets: France, Spain, Belgium, Canada.
• Founded: 2016.

Why it matters

Alan's raise demonstrates that European healthtech can scale at venture-equivalent speed inside a heavily regulated insurance framework, a combination most US investors assumed was impossible. The Prosus anchor, from a non-European but non-US fund, also indicates that global crossover capital is no longer passing over regulated European consumer platforms. If AMF sign-off clears, Alan will be the first European healthtech at this scale to have demonstrated insurance profitability, a bar that competitors in the US health-tech sector have repeatedly failed to clear.

What to watch

• AMF regulatory approval timeline, the condition blocking the round from closing fully.
• Whether Alan launches in Germany, the UK or another major European market as the next growth step.
• IPO preparation: at €5.5bn, Alan is at the scale where a Paris or Amsterdam listing becomes plausible within 18 months.
• Whether Prosus's ownership stake creates a path toward a strategic acquisition rather than an independent IPO.